Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
Medical Xpress
February 26, 2026
AI-Generated Deep Dive Summary
An international clinical trial has revealed that oral semaglutide, a widely used diabetes medication, significantly reduces the risk of serious heart failure events in people with type 2 diabetes who have already experienced heart failure. The study, conducted as part of the Semaglutide Cardiovascular Outcomes (SOUL) Trial, involved nearly 9,650 adults with type 2 diabetes and either cardiovascular disease or chronic kidney disease. Participants were followed for nearly four years, and the results showed that those taking oral semaglutide experienced a 26% reduction in the risk of hospitalization for heart failure compared to those on a placebo.
The trial highlights the importance of evaluating medications not just for their primary therapeutic effects but also for potential cardiovascular benefits or risks. Semaglutide, an GLP-1 receptor agonist, is already known for its role in managing blood sugar levels and promoting weight loss. However, this study focuses on its impact on heart health, a critical concern for individuals with type 2 diabetes, who are at higher risk of cardiovascular complications.
The findings from the SOUL Trial underscore the potential of oral semaglutide to address a significant unmet need in diabetes care. By reducing the likelihood of serious heart failure events, the drug offers an additional layer of protection for patients who may already be managing multiple chronic conditions. This makes it a valuable addition to the treatment arsenal for healthcare providers aiming to improve overall patient outcomes.
For individuals with type 2 diabetes and existing cardiovascular or kidney issues, the results of this trial provide reassurance that oral semaglutide could play a crucial role in mitigating heart failure risks. As more research continues to explore the broader benefits of GLP-1 receptor agonists, patients and healthcare providers can feel confident in the evidence supporting their use beyond blood sugar management.
In summary, the
Verticals
healthmedical
Originally published on Medical Xpress on 2/26/2026